Try our beta test site
11 studies found for:    radioimmunotherapy AND lymphoma | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Phase III Multicenter, Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Versus Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL)
Condition: Relapsed Follicular Lymphoma
Interventions: Other: ZEVALIN;   Drug: BEAM
2 Not yet recruiting Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Condition: Non-Hodgkin Lymphoma
Interventions: Drug: Betalutin with HH1 pre-dosing;   Drug: Betalutin with Rituximab pre-dosing
3 Recruiting A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Betalutin
4 Recruiting A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Condition: Relapsed or Refractory Diffuse Large B Cell Lymphoma
Intervention: Drug: 131I-rituximab
5 Recruiting Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma
Conditions: Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage II Grade 1 Contiguous Follicular Lymphoma;   Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Stage II Grade 2 Contiguous Follicular Lymphoma;   Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab;   Radiation: Yttrium Y-90 Ibritumomab Tiuxetan
6 Recruiting 131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
Condition: Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma
Intervention: Drug: 131I-rituximab
7 Recruiting Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Conditions: Adult Burkitt Lymphoma;   Adult Diffuse Large B-Cell Lymphoma;   CD20-Positive Neoplastic Cells Present;   Indolent Adult Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions: Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Clearing Agent;   Drug: Cytarabine;   Drug: Etoposide;   Radiation: Indium In 111-DOTA-Biotin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Yttrium Y 90-DOTA-Biotin
8 Recruiting Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BAY1862864
9 Recruiting Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-05)
Condition: Relapsed, Diffuse Large B-cell Lymphoma
Intervention: Drug: Betalutin
10 Recruiting Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy
Conditions: Acute Leukaemia;   Chronic Leukaemia;   Myeloma;   Lymphoma
Intervention: Radiation: Targeted radiotherapy
11 Recruiting Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   CD45-Positive Neoplastic Cells Present;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Radiation: Iodine I 131 Monoclonal Antibody BC8;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation

Study has passed its completion date and status has not been verified in more than two years.